Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis

Ying Wei, Thomas J. Kim, David H. Peng, Dana Duan, Don L. Gibbons, Mitsuo Yamauchi, Julia R. Jackson, Claude T Chapman, Cheresa Calhoun, Jay I Peters, Rik Derynck, Bradley J. Backes, Harold A. Chapman

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

TGF-β1 signaling is a critical driver of collagen accumulation and fibrotic disease but also a vital suppressor of inflammation and epithelial cell proliferation. The nature of this multifunctional cytokine has limited the development of global TGF-β1 signaling inhibitors as therapeutic agents. We conducted phenotypic screens for small molecules that inhibit TGF-β1-induced epithelial-mesenchymal transition without immediate TGF-β1 receptor (TβR) kinase inhibition. We identified trihydroxyphenolic compounds as potent blockers of TGF-β1 responses (IC50 ∼50 nM), Snail1 expression, and collagen deposition in vivo in models of pulmonary fibrosis and collagen-dependent lung cancer metastasis. Remarkably, the functional effects of trihydroxyphenolics required the presence of active lysyl oxidase-like 2 (LOXL2), thereby limiting effects to fibroblasts or cancer cells, the major LOXL2 producers. Mechanistic studies revealed that trihydroxyphenolics induce autooxidation of a LOXL2/3-specific lysine (K731) in a time-dependent reaction that irreversibly inhibits LOXL2 and converts the trihydrophenolic to a previously undescribed metabolite that directly inhibits TβRI kinase. Combined inhibition of LOXL2 and TβRI activities by trihydrophenolics resulted in potent blockade of pathological collagen accumulation in vivo without the toxicities associated with global inhibitors. These findings elucidate a therapeutic approach to attenuate fibrosis and the disease-promoting effects of tissue stiffness by specifically targeting TβRI kinase in LOXL2-expressing cells.

Original languageEnglish (US)
Pages (from-to)3675-3688
Number of pages14
JournalJournal of Clinical Investigation
Volume127
Issue number10
DOIs
StatePublished - Oct 2 2017

Fingerprint

Protein-Lysine 6-Oxidase
Fibrosis
Fibroblasts
Lung
Collagen
Neoplasms
Phosphotransferases
Epithelial-Mesenchymal Transition
Pulmonary Fibrosis
Inhibitory Concentration 50
Lysine
Lung Neoplasms
Epithelial Cells
Cell Proliferation
Cytokines
Neoplasm Metastasis
Inflammation
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wei, Y., Kim, T. J., Peng, D. H., Duan, D., Gibbons, D. L., Yamauchi, M., ... Chapman, H. A. (2017). Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis. Journal of Clinical Investigation, 127(10), 3675-3688. https://doi.org/10.1172/JCI94624

Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis. / Wei, Ying; Kim, Thomas J.; Peng, David H.; Duan, Dana; Gibbons, Don L.; Yamauchi, Mitsuo; Jackson, Julia R.; Chapman, Claude T; Calhoun, Cheresa; Peters, Jay I; Derynck, Rik; Backes, Bradley J.; Chapman, Harold A.

In: Journal of Clinical Investigation, Vol. 127, No. 10, 02.10.2017, p. 3675-3688.

Research output: Contribution to journalArticle

Wei, Y, Kim, TJ, Peng, DH, Duan, D, Gibbons, DL, Yamauchi, M, Jackson, JR, Chapman, CT, Calhoun, C, Peters, JI, Derynck, R, Backes, BJ & Chapman, HA 2017, 'Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis', Journal of Clinical Investigation, vol. 127, no. 10, pp. 3675-3688. https://doi.org/10.1172/JCI94624
Wei, Ying ; Kim, Thomas J. ; Peng, David H. ; Duan, Dana ; Gibbons, Don L. ; Yamauchi, Mitsuo ; Jackson, Julia R. ; Chapman, Claude T ; Calhoun, Cheresa ; Peters, Jay I ; Derynck, Rik ; Backes, Bradley J. ; Chapman, Harold A. / Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis. In: Journal of Clinical Investigation. 2017 ; Vol. 127, No. 10. pp. 3675-3688.
@article{fba84d290d7f40399f609228ee1b6b3b,
title = "Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis",
abstract = "TGF-β1 signaling is a critical driver of collagen accumulation and fibrotic disease but also a vital suppressor of inflammation and epithelial cell proliferation. The nature of this multifunctional cytokine has limited the development of global TGF-β1 signaling inhibitors as therapeutic agents. We conducted phenotypic screens for small molecules that inhibit TGF-β1-induced epithelial-mesenchymal transition without immediate TGF-β1 receptor (TβR) kinase inhibition. We identified trihydroxyphenolic compounds as potent blockers of TGF-β1 responses (IC50 ∼50 nM), Snail1 expression, and collagen deposition in vivo in models of pulmonary fibrosis and collagen-dependent lung cancer metastasis. Remarkably, the functional effects of trihydroxyphenolics required the presence of active lysyl oxidase-like 2 (LOXL2), thereby limiting effects to fibroblasts or cancer cells, the major LOXL2 producers. Mechanistic studies revealed that trihydroxyphenolics induce autooxidation of a LOXL2/3-specific lysine (K731) in a time-dependent reaction that irreversibly inhibits LOXL2 and converts the trihydrophenolic to a previously undescribed metabolite that directly inhibits TβRI kinase. Combined inhibition of LOXL2 and TβRI activities by trihydrophenolics resulted in potent blockade of pathological collagen accumulation in vivo without the toxicities associated with global inhibitors. These findings elucidate a therapeutic approach to attenuate fibrosis and the disease-promoting effects of tissue stiffness by specifically targeting TβRI kinase in LOXL2-expressing cells.",
author = "Ying Wei and Kim, {Thomas J.} and Peng, {David H.} and Dana Duan and Gibbons, {Don L.} and Mitsuo Yamauchi and Jackson, {Julia R.} and Chapman, {Claude T} and Cheresa Calhoun and Peters, {Jay I} and Rik Derynck and Backes, {Bradley J.} and Chapman, {Harold A.}",
year = "2017",
month = "10",
day = "2",
doi = "10.1172/JCI94624",
language = "English (US)",
volume = "127",
pages = "3675--3688",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "10",

}

TY - JOUR

T1 - Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis

AU - Wei, Ying

AU - Kim, Thomas J.

AU - Peng, David H.

AU - Duan, Dana

AU - Gibbons, Don L.

AU - Yamauchi, Mitsuo

AU - Jackson, Julia R.

AU - Chapman, Claude T

AU - Calhoun, Cheresa

AU - Peters, Jay I

AU - Derynck, Rik

AU - Backes, Bradley J.

AU - Chapman, Harold A.

PY - 2017/10/2

Y1 - 2017/10/2

N2 - TGF-β1 signaling is a critical driver of collagen accumulation and fibrotic disease but also a vital suppressor of inflammation and epithelial cell proliferation. The nature of this multifunctional cytokine has limited the development of global TGF-β1 signaling inhibitors as therapeutic agents. We conducted phenotypic screens for small molecules that inhibit TGF-β1-induced epithelial-mesenchymal transition without immediate TGF-β1 receptor (TβR) kinase inhibition. We identified trihydroxyphenolic compounds as potent blockers of TGF-β1 responses (IC50 ∼50 nM), Snail1 expression, and collagen deposition in vivo in models of pulmonary fibrosis and collagen-dependent lung cancer metastasis. Remarkably, the functional effects of trihydroxyphenolics required the presence of active lysyl oxidase-like 2 (LOXL2), thereby limiting effects to fibroblasts or cancer cells, the major LOXL2 producers. Mechanistic studies revealed that trihydroxyphenolics induce autooxidation of a LOXL2/3-specific lysine (K731) in a time-dependent reaction that irreversibly inhibits LOXL2 and converts the trihydrophenolic to a previously undescribed metabolite that directly inhibits TβRI kinase. Combined inhibition of LOXL2 and TβRI activities by trihydrophenolics resulted in potent blockade of pathological collagen accumulation in vivo without the toxicities associated with global inhibitors. These findings elucidate a therapeutic approach to attenuate fibrosis and the disease-promoting effects of tissue stiffness by specifically targeting TβRI kinase in LOXL2-expressing cells.

AB - TGF-β1 signaling is a critical driver of collagen accumulation and fibrotic disease but also a vital suppressor of inflammation and epithelial cell proliferation. The nature of this multifunctional cytokine has limited the development of global TGF-β1 signaling inhibitors as therapeutic agents. We conducted phenotypic screens for small molecules that inhibit TGF-β1-induced epithelial-mesenchymal transition without immediate TGF-β1 receptor (TβR) kinase inhibition. We identified trihydroxyphenolic compounds as potent blockers of TGF-β1 responses (IC50 ∼50 nM), Snail1 expression, and collagen deposition in vivo in models of pulmonary fibrosis and collagen-dependent lung cancer metastasis. Remarkably, the functional effects of trihydroxyphenolics required the presence of active lysyl oxidase-like 2 (LOXL2), thereby limiting effects to fibroblasts or cancer cells, the major LOXL2 producers. Mechanistic studies revealed that trihydroxyphenolics induce autooxidation of a LOXL2/3-specific lysine (K731) in a time-dependent reaction that irreversibly inhibits LOXL2 and converts the trihydrophenolic to a previously undescribed metabolite that directly inhibits TβRI kinase. Combined inhibition of LOXL2 and TβRI activities by trihydrophenolics resulted in potent blockade of pathological collagen accumulation in vivo without the toxicities associated with global inhibitors. These findings elucidate a therapeutic approach to attenuate fibrosis and the disease-promoting effects of tissue stiffness by specifically targeting TβRI kinase in LOXL2-expressing cells.

UR - http://www.scopus.com/inward/record.url?scp=85030571617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030571617&partnerID=8YFLogxK

U2 - 10.1172/JCI94624

DO - 10.1172/JCI94624

M3 - Article

VL - 127

SP - 3675

EP - 3688

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 10

ER -